You can also add to your health journal encourading news about advances in the myeloma management. Here are some of them:
Antibody treatment resulted in 100% remission in patients with multiple myeloma
Scientists from the University of Miami, led by Dikran Kazanjian, in 2025 presented the results of a pilot clinical trial using antibodies to combat multiple myeloma. They developed the antibody linvoseltamab, which binds to several targets on immune and cancer cells, enhancing the immune response to the tumor. Participants received four to six cycles of linvoseltamab treatment after standard treatment. All had positive tests for residual malignant cells before starting antibody treatment. Treatment showed a 100% absence of any traces of cancer after completing the linvoseltamab course in all participants. Only a few experienced mild side effects, including decreased white blood cell counts and upper respiratory tract infections. Scientists are very encouraged by the therapy's effectiveness and safety profile. They have already expanded the next recruitment to 50 participants.
Virus destroyed all the cancer cells. The woman recovered.
Remember how the bandits killed the vampires in the movie "From Dusk Till Dawn"? Something similar happened to 50-year-old American Stacy Erholtz in 2014. She suffered from myeloma (bone marrow cancer), which caused her frontal bone to grow and press on her brain. Neither chemotherapy nor stem cell therapy helped. Then, doctors at the Maya Clinic (as part of a clinical trial) administered a shock dose of a modified measles virus. At first, Stacy had to endure a severe fever, but eventually (after a few weeks), the tumor on her forehead disappeared, as did metastases in other parts of her body. The virus destroyed all the cancer cells. This is said to be the first successful use of virus therapy in humans. Until now, only mice had been treated this way.
New drug developed for the treatment of multiple myeloma
American pharmaceutical giant Celgene in 2012 submitted an application to the FDA for approval of a new drug for the treatment of multiple myeloma – the latest-generation immunomodulator pomalidomide. The drug has proved to be effective in patients with multiple myeloma whose bodies do not respond to other therapies (for example, bortezomib and lenalidomide). Pomalidomide is an oral drug with multiple mechanisms of action, including both tumor cell destruction and immune stimulation. Clinical trials have confirmed a high response rate (98%) and duration of response, as well as increased progression-free survival in patients who previously received multiple lines of therapy with bortezomib and lenalidomide. An application for approval in Europe is also expected to be submitted in 2012 and the drug will be available to patients in need as early as next year.